- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about GILD
Recent news which mentions GILD
From Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
From Benzinga
Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
February 02, 2022
Tickers
GILD
From Benzinga
Gilead Sciences (GILD) Q4 2021 Earnings Call Transcript
February 02, 2022
Tickers
GILD
From Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 01, 2022
From Benzinga
Gilead earnings slammed by legal settlement, stock falls
February 01, 2022
From MarketWatch
Is AbbVie Stock a Buy Now?
February 01, 2022
From Motley Fool
What This FDA News Could Mean for Pfizer
February 01, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 31, 2022
From Benzinga
How to Invest in Biotech When Deep Value Has no Discernible Meaning
January 31, 2022
From Motley Fool
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
3 Growth ETFs to Consider Buying During This Correction
January 29, 2022
From Motley Fool
What 5 Analyst Ratings Have To Say About Gilead Sciences
January 28, 2022
Tickers
GILD
From Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
January 26, 2022
From Benzinga
FDA Puts Clinical Hold On Gilead's Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
January 26, 2022
Tickers
GILD
From Benzinga
Why Sierra Oncology Stock Is On Fire Today
January 25, 2022
From Motley Fool
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
January 24, 2022
From Benzinga
From Benzinga
FDA Approves Gilead's Remdesivir For Non-Hospitalized COVID-19 Patients At High Risk For Disease Progression
January 24, 2022
Tickers
GILD
From Benzinga
From Benzinga
South Africa study shows boosters failed to block omicron, bolstering case for face masks, distancing and hand washing
January 20, 2022
From MarketWatch
We need a decisive pivot on COVID-19: Double down on treatments for those at high risk instead of boosters and tests for everyone
January 20, 2022
From MarketWatch
Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs
January 19, 2022
Tickers
GILD
From Benzinga
Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US
January 18, 2022
Tickers
GILD
From Benzinga
3 Pharma Stocks With Especially Juicy Dividends
January 16, 2022
From Motley Fool
2 Top Healthcare Stocks to Buy Right Now
January 14, 2022
From Motley Fool
4 Biotech Acquisitions We'd Like to See in 2022
January 14, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.